Establishment Labs

Establishment Labs has delivered over four million Motiva® devices since their commercial launch in 2010. The company’s flagship products—Motiva SmoothSilk Ergonomix and SmoothSilk Round breast implants—received FDA approval in September 2024 after demonstrating lower complication rates than competitors in clinical trials. Their minimally invasive Mia Femtech™ procedure and new Preservé™ technology are designed to improve safety profiles, reduce recovery times, minimize scarring, preserve breast sensation, and achieve more natural results compared to traditional methods. The company supports its innovations with a robust patent portfolio (>200 applications) and extensive clinical data (>100 studies/publications).